Jason Butler
Stock Analyst at Citizens
(4.67)
# 169
Out of 5,138 analysts
141
Total ratings
52.32%
Success rate
45.29%
Average return
Main Sectors:
Stocks Rated by Jason Butler
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IRWD Ironwood Pharmaceuticals | Upgrades: Market Outperform | $8 | $4.52 | +76.99% | 2 | Jan 5, 2026 | |
| CYTK Cytokinetics | Maintains: Market Outperform | $78 → $88 | $63.44 | +38.72% | 17 | Dec 22, 2025 | |
| NSRX Nasus Pharma | Initiates: Market Outperform | $19 | $7.10 | +167.61% | 1 | Dec 18, 2025 | |
| ABVX ABIVAX Société Anonyme | Maintains: Market Outperform | $114 → $131 | $116.80 | +12.16% | 5 | Dec 16, 2025 | |
| PRTA Prothena Corporation | Maintains: Market Outperform | $11 → $19 | $9.26 | +105.18% | 12 | Dec 1, 2025 | |
| HALO Halozyme Therapeutics | Maintains: Market Outperform | $91 → $92 | $71.82 | +28.10% | 14 | Nov 4, 2025 | |
| AQST Aquestive Therapeutics | Maintains: Market Outperform | $9 → $12 | $3.34 | +259.28% | 8 | Oct 9, 2025 | |
| RAPP Rapport Therapeutics | Reiterates: Market Outperform | $28 | $26.86 | +4.24% | 2 | Jul 8, 2025 | |
| ACAD ACADIA Pharmaceuticals | Reiterates: Market Outperform | $37 | $26.53 | +39.46% | 15 | Jun 26, 2025 | |
| GHRS GH Research | Reiterates: Market Outperform | $39 | $16.96 | +129.95% | 5 | Jun 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $6 | $4.14 | +44.93% | 11 | Jun 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $115 → $100 | $36.23 | +176.01% | 1 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $42 → $38 | $33.03 | +15.05% | 8 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $17 → $18 | $9.02 | +99.56% | 2 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $4 | $3.13 | +27.80% | 7 | Mar 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $696 → $701 | $813.24 | -13.80% | 8 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $29 → $33 | $15.62 | +111.27% | 1 | Feb 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $8 → $9 | $2.81 | +220.28% | 8 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $19 | $7.01 | +171.04% | 6 | Apr 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $4.33 | - | 1 | Oct 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Outperform | $42,000 | $10.66 | +393,896.25% | 1 | Dec 15, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $111 → $116 | $13.35 | +768.91% | 4 | Nov 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $7 → $9 | $4.70 | +91.49% | 1 | Nov 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.59 | - | 1 | Dec 2, 2020 |
Ironwood Pharmaceuticals
Jan 5, 2026
Upgrades: Market Outperform
Price Target: $8
Current: $4.52
Upside: +76.99%
Cytokinetics
Dec 22, 2025
Maintains: Market Outperform
Price Target: $78 → $88
Current: $63.44
Upside: +38.72%
Nasus Pharma
Dec 18, 2025
Initiates: Market Outperform
Price Target: $19
Current: $7.10
Upside: +167.61%
ABIVAX Société Anonyme
Dec 16, 2025
Maintains: Market Outperform
Price Target: $114 → $131
Current: $116.80
Upside: +12.16%
Prothena Corporation
Dec 1, 2025
Maintains: Market Outperform
Price Target: $11 → $19
Current: $9.26
Upside: +105.18%
Halozyme Therapeutics
Nov 4, 2025
Maintains: Market Outperform
Price Target: $91 → $92
Current: $71.82
Upside: +28.10%
Aquestive Therapeutics
Oct 9, 2025
Maintains: Market Outperform
Price Target: $9 → $12
Current: $3.34
Upside: +259.28%
Rapport Therapeutics
Jul 8, 2025
Reiterates: Market Outperform
Price Target: $28
Current: $26.86
Upside: +4.24%
ACADIA Pharmaceuticals
Jun 26, 2025
Reiterates: Market Outperform
Price Target: $37
Current: $26.53
Upside: +39.46%
GH Research
Jun 24, 2025
Reiterates: Market Outperform
Price Target: $39
Current: $16.96
Upside: +129.95%
Jun 12, 2025
Reiterates: Market Outperform
Price Target: $6
Current: $4.14
Upside: +44.93%
May 9, 2025
Maintains: Market Outperform
Price Target: $115 → $100
Current: $36.23
Upside: +176.01%
May 7, 2025
Maintains: Market Outperform
Price Target: $42 → $38
Current: $33.03
Upside: +15.05%
Mar 12, 2025
Maintains: Market Outperform
Price Target: $17 → $18
Current: $9.02
Upside: +99.56%
Mar 5, 2025
Reiterates: Market Outperform
Price Target: $4
Current: $3.13
Upside: +27.80%
Feb 28, 2025
Maintains: Outperform
Price Target: $696 → $701
Current: $813.24
Upside: -13.80%
Feb 21, 2025
Maintains: Market Outperform
Price Target: $29 → $33
Current: $15.62
Upside: +111.27%
Feb 13, 2025
Maintains: Market Outperform
Price Target: $8 → $9
Current: $2.81
Upside: +220.28%
Apr 9, 2024
Reiterates: Market Outperform
Price Target: $19
Current: $7.01
Upside: +171.04%
Oct 17, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $4.33
Upside: -
Dec 15, 2021
Initiates: Market Outperform
Price Target: $42,000
Current: $10.66
Upside: +393,896.25%
Nov 23, 2021
Maintains: Market Outperform
Price Target: $111 → $116
Current: $13.35
Upside: +768.91%
Nov 8, 2021
Maintains: Market Outperform
Price Target: $7 → $9
Current: $4.70
Upside: +91.49%
Dec 2, 2020
Downgrades: Market Perform
Price Target: n/a
Current: $1.59
Upside: -